newsfilter
← Latest News
Business Wire·

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of